ARVINAS INC. - COMMON

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

30 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 Jun 2024 15:37:13 By Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 Jun 2024 06:00:51 By Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 Jun 2024 06:00:03 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

23 May 2024 16:00:15 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16 May 2024 05:00:45 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09 May 2024 15:42:04 By Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 May 2024 06:00:11 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

02 May 2024 06:00:00 By Nasdaq GlobeNewswire

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 Apr 2024 15:30:38 By Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 Apr 2024 06:00:49 By Nasdaq GlobeNewswire

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

18 Mar 2024 15:40:46 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 Mar 2024 06:00:04 By Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 Feb 2024 06:00:07 By Nasdaq GlobeNewswire

Arvinas Announces Chief Financial Officer Transition

20 Feb 2024 15:05:04 By Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 Feb 2024 06:00:44 By Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 Feb 2024 05:45:00 By Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 Feb 2024 15:30:20 By Nasdaq GlobeNewswire

Arvinas Appoints Jared Freedberg as General Counsel

16 Jan 2024 16:01:06 By Nasdaq GlobeNewswire